InnoCan Pharma Corporation

INNO

CA45783P5085

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 03:34:56 2025-12-05 pm EST			5-day change	1st Jan Change
10.80 ^CAD	+5.99%		+8.11%	-20.88%

Nov. 27	Innocan Pharma Nine-month Operating Loss Stable, Revenue Fall 10%	MT
Nov. 26	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Innocan Pharma's LPT-CBD Shows Success in Relieving Osteoarthritis Pain in Dogs

Published on 10/11/2024 at 04:29 pm EDT - Modified on 10/11/2024 at 04:53 pm EDT

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about InnoCan Pharma Corporation

Nov. 27	Innocan Pharma Nine-month Operating Loss Stable, Revenue Fall 10%	MT
Nov. 26	InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 24	Innocan Pharma Corporation Announces Promising Translational Evidence from A Pain Relief Study of Repeated Lpt-Cbd Administration in Goats	CI
Oct. 15	Innocan Pharma Corporation Announces Its Patent for Lpt-Cbd Is Allowed in Japan	CI
Sep. 18	Innocan Pharma Corporation Partners with Freedom Farm to Bring Remedy and Hope with its LPT-CBD Injection	CI
Aug. 29	InnoCan Pharma Plans One-for-65 Share Consolidation Ahead of Nasdaq Listing	MT
Aug. 29	Innocan Pharma announces details of proposed share consolidation	RE
Aug. 27	InnoCan Pharma Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
Aug. 27	Innocan Pharma announces first half of 2025 financial results	RE
Aug. 27	Innocan Pharma announces first half of 2025 financial results	RE
Aug. 22	Innocan Pharma Corporation to Showcase a Poster Outlining Key Data on LPT-CBD Pharmacokinetics and Efficacy Along with the Recently Published Narrative Review	CI
Jul. 23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
Jul. 23	Innocan Pharma announces public filing of registration statement for proposed U.S. public offering	RE
Jul. 03	Chair of Innocan Pharma Resigns	MT
Jul. 03	InnoCan Pharma Corporation Announces Executive Changes, Effective July 1, 2025	CI
Jul. 03	InnoCan Pharma Corporation Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs	CI
Jun. 20	Innocan Pharma to Present Review on Synthetic Cannabidiol for Chronic Pain at PAINWEEK 2025	MT
Jun. 20	Innocan Pharma Corporation Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference	CI
Jun. 13	Innocan Pharma Endorses Liposomal Synthetic CBD for Chronic Pain Review	MT
May. 28	InnoCan Pharma Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
May. 28	InnoCan Swings To Q1 Profit On Higher Revenues	MT
May. 06	Innocan Pharma Corporation First Granted Patent in Mexico for Its Topical Pain Relief	CI
Apr. 15	Innocan Pharma Announces Closing Of Private Placement	RE
Apr. 14	InnoCan Pharma Corporation announced that it has received CAD 0.214839 million in funding	CI
Apr. 07	Innocan Pharma Corporation Announces Divisional Application for Its Liposomal Liposome-Based CBD Technology Patent	CI

Chart InnoCan Pharma Corporation

Duration

Period

INNO: Dynamic Chart

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, the Company develops and markets a wide portfolio of high-performance self-care and beauty products to promote a healthier lifestyle. Under this segment Innocan established a Joint Venture (BI Sky Global Ltd.) that focused on advanced, targeted online sales.

Employees

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release (Projected)

More about the company